BioCentury
ARTICLE | Finance

China’s early stage Panacea

How Panacea plans to deploy funds to back early stage biotech, medtech in China

April 21, 2018 12:01 AM UTC

Despite a recent wave of large funds investing in Chinese biotechs, new Chinese VC Panacea Venture believes a pair of funds totaling roughly $300 million is more than enough to pursue its early stage investing and company formation strategy in Chinese life sciences.

Panacea, which was formed through the spin out of KPCB China’s life sciences team at the end of last year, is led by James Huang, who has been a managing partner at the firm since 2011...